LONZA (THAILAND) CO LTD

Company Introduction for LONZA (THAILAND) CO LTD

Company Type: Manufacturing Facility / Factory

LONZA (THAILAND) CO LTD is a manufacturing facility operating as a direct subsidiary of the Lonza Group, a globally recognized leader in the biotechnology and specialty ingredients sectors.

Based in Thailand, this company serves as a key production site within Lonza's extensive global manufacturing network. It is primarily involved in the production and processing of specialized ingredients, which are critical components for various industries. These include, but are not limited to, nutrition and health products, personal care applications, and advanced materials.

As a manufacturing plant, LONZA (THAILAND) CO LTD focuses on transforming raw materials into high-quality, finished specialty ingredients, adhering to the stringent global quality, safety, and environmental standards established by the Lonza Group. Its operations contribute to Lonza's mission of providing innovative solutions and essential components to its worldwide customer base.

LONZA (THAILAND) CO LTD is primarily involved in the sale and production of products related to Lonza's **Capsules & Health Ingredients** segment, which serves the pharmaceutical and nutraceutical markets.

Specific products and capabilities associated with the Lonza entity in Thailand include:

* **Capsugel Capsules:** Hard empty capsules for oral and inhaled medicines and over-the-counter products.

* **Vcaps Plus Capsules:** HPMC capsules (developed without gelling agents) for the pharmaceutical industry.

* **Vcaps Enteric Capsules:** Functional capsules providing enteric protection and delayed release without an enteric coating.

* **CAPSUGEL ZEPHYR:** Dry-powder inhalation (DPI) technology for respiratory or systemic drug delivery.

* **Organicaps Capsules:** A specific type of Capsugel capsule (mentioned with the Bangkok location).

The company is also part of Lonza's wider global operations as a **Contract Development and Manufacturing Organization (CDMO)**, which broadly encompasses services and products across:

* **Integrated Biologics:** Mammalian development, manufacturing, and licensing technologies.

* **Advanced Synthesis:** Small molecules, Highly Potent Active Pharmaceutical Ingredients (HPAPIs), and bioconjugates.

* **Specialized Modalities:** Cell and gene therapy (CGT), mRNA, and microbial technologies.

* **Bioscience Products:** Tools for life science research, including primary cells, cell culture and transfection tools, protein production media, and endotoxin/pyrogen testing solutions.